Janssen Presents Results of Rybrevant (amivantamab-vmjw) in P-I CHRYSALIS Study for Advanced NSCLC with METex14 Mutations at WCLC Published: Aug 20, 2021 | Tags: Astellas, FibroGen, Evrenzo, Roxadustat, EC, Approval, […]readmore
Tags : Adagene
Shots: The companies collaborated to evaluate ADG106 + Keytruda in dose-escalation and expansion clinical study to treat advanced or metastatic solid tumors & hematological malignancies In preclinical studies, ADG106 showed […]readmore
Shots: Adagene to receive upfront, development & commercial milestones, research funding and royalties on sales with certain commercialization rights for Greater China. ADC Therapeutics to utilize Adagene’s SAFEbody technology generating […]readmore